Teva and Heptares enter $400m agreement for small-molecule migraine treatment
pharmafile | November 25, 2015 | News story | Research and Development | Heptares, Teva, collaboration, migraine
Teva Pharmaceuticals and Heptares Therapeutics have signed a licensing and drug-discovery agreement for Teva to gain exclusive global rights to develop, manufacture and commercialise new migraine treatments.
Israeli-based Teva and Heptares, which is a wholly owned subsidiary of Sosei Group Corporation, struck the deal for novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine.
Under the terms of the agreement, Heptares will receive an upfront payment of $10 million, research funding, and is eligible to receive additional research, development and commercialization milestone payments of up to $400 million. In addition, Heptares will be eligible to receive royalties on net sales of products resulting from the alliance.
Michael Hayden, president of global R&D and chief scientific officer at Teva says: “We are delighted to begin this partnership with Heptares, which through its industry-leading, structure-based design approach has generated novel CGRP antagonists with significant promise for treating migraine.”
“CGRP antagonism represents an exciting opportunity to treat migraine. We believe small-molecule CGRP antagonists offer further opportunities that are highly complementary to our promising candidate, TEV-48125, an anti-CGRP antibody.”
Malcolm Weir, chief executive officer of Heptares says: “This agreement is an exciting development for our CGRP antagonist program. Teva brings world-leading clinical and commercial expertise in migraine to advance this program based on differentiated small-molecule CGRP antagonists discovered using our novel structure-based drug design technologies. The commitment Teva is making allows us to expand this promising program.”
Yasmita Kumar
Related Content
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
